ArticleMedicina (Kaunas, Lithuania)2022
Sex Difference in Cutoff and Prevalence of Sarcopenia among 300,090 Urban Korean Population: Association with Metabolic Syndrome.
Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Sex-Specific Differences in Patients with Sarcopenia and Peripheral Artery Disease.Muscles (Basel, Switzerland) · 2026Article
- The impact of metabolic syndrome on changes in trunk muscle CSA: a 10-year longitudinal study.Journal of bone and mineral metabolism · 2026Article
- Association between estimated glucose disposal rate and sarcopenia in U.S. adults: a cross-sectional study based on NHANES 2011-2018.Diabetology & metabolic syndrome · 2026Article
- Global prevalence of metabolic syndrome among individuals with sarcopenia: a systematic review and meta-analysis of 72,129 patients.Diabetology & metabolic syndrome · 2026Review
- Association between serum uric acid and muscle function in underweight young women: An exploratory cross-sectional study.PloS one · 2026Article
- Article
- Prevalence and Fall Risk of Sarcopenia Based on the 2023 Korean Working Group on Sarcopenia Criteria.Medicina (Kaunas, Lithuania) · 2025Article
- Epidemiology of sarcopenia: A narrative review.Osteoporosis and sarcopenia · 2025Review
- The Critical Role of Body Composition Assessment in Advancing Research and Clinical Health Risk Assessment across the Lifespan.Journal of obesity & metabolic syndrome · 2025Review
- Oxidative balance score is associated with increased risk of sarcopenia and sarcopenic obesity in non-elderly adults: results from NHANES 2011-2018.Nutrition & metabolism · 2025Article
- Serum calcium levels and the risk of sarcopenia in young adults: insights from NHANES 2011-2018.Frontiers in nutrition · 2025Article
- Associations of metabolic syndrome and its components with sarcopenia, and the mediating role of insulin resistance: Findings from NHANES database.BMC endocrine disorders · 2024Article
- Possible sarcopenia and risk of new-onset type 2 diabetes mellitus in older adults in China: a 7-year longitudinal cohort study.BMC geriatrics · 2023Article
- Muscle distribution in relation to all-cause and cause-specific mortality in young and middle-aged adults.Journal of translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: The study aimed to establish the threshold values and prevalence of sarcopenia and to investigate the association of sarcopenia with metabolic syndrome in an urban Korean population. Materials and Methods: The study included 300,090 adults who underwent anthropometric analyses by bioelectrical impedance analyzer. Sarcopenia was defined as: (1) class I, skeletal muscle mass index (SMI) within −1 to −2 standard deviations (SDs); (2) or class II, <−2 SD of SMI in a young population. Results: Low SMI threshold levels for class I and class II sarcopenia were 39.8 and 36.7% in men, and 35.5 and 32.3% in women. Among all age groups, the prevalence rates of sarcopenia were highest in the age group 80−89 years. Following adjustment for possible confounders including age, sex, height, metabolic and health behavioral factors, adjusted odds ratios (95% confidence intervals) for the risk of metabolic syndrome were 2.43 (2.33−2.54) for class I and 2.69 (2.49−2.91) for class II sarcopenia, compared with the normal reference. Sarcopenia was more strongly associated with metabolic syndrome in women than men (p for interaction < 0.01). The threshold values and prevalence of sarcopenia were demonstrated in a large Korean urban population. Conclusions: This study identified that sarcopenia was associated with increased risk of metabolic syndrome, showing itself to be significantly higher in women than men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.